Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

Michel Bolla*, Philippe Maingon, Christian Carrie, Salvador Villa, Petros Kitsios, Philip M. P. Poortmans, Santhanam Sundar, Elzbieta M. van der Steen-Banasik, John Armstrong, Jean-Francois Bosset, Fernanda G. Herrera, Bradley Pieters, Annerie Slot, Amit Bahl, Rahamim Ben-Yosef, Dirk Boehmer, Christopher Scrase, Laurette Renard, Emad Shash, Corneel CoensAlphonsus C. M. van den Bergh, Laurence Collette

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

153 Citaten (Scopus)



Up to 30% of patients who undergo radiation for intermediate-or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate-or high-risk localized prostate cancer.

Patients and Methods

A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) >= 10 ng/mL or Gleason >= 7, or (2) cT2a (International Union Against Cancer TNM1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA


The median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; P


Six months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation.

Originele taal-2English
Pagina's (van-tot)1748-1756
Aantal pagina's22
TijdschriftJournal of Clinical Oncology
Nummer van het tijdschrift15
StatusPublished - 20-mei-2016

Citeer dit